RG-8803

N/A

Report date: 2022/08/24 20:00:31

Base Information

Drug NameRG-8803
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiogenesis inhibitorsEpidermal growth factor inhibitorsFibroblast growth factors antagonists
TargetsFibroblast growth factorsEpidermal growth factor
Therapy Area/IndicationsDiabetic RetinopathyNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRepligen
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRepligen
Active IndicationsN/A
Inactive IndicationsDiabetic RetinopathyNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A